Robert W. Yeh, MD, FACC
Beth Israel Deaconess Medical Center

Printed as of 11/28/2026

Disclosures

Personal Commercial (12)

Company Name	Relationship Category	Compensation Level	*Topic Area(s)*
Self			
Abbott Laboratories	Research/Research Grants	Significant (>= $5,000)	*Invasive CV Angio and Interventions*
Abbott Vascular	Consultant Fees/Honoraria	Significant (>= $5,000)	*Invasive CV Angio and Interventions*
Baim Institute for Clinical Research	Salary	Significant (>= $5,000)	*Invasive CV Angio and Interventions* *General Cardiology*
Boston Scientific	Consultant Fees/Honoraria	Significant (>= $5,000)	*Invasive CV Angio and Interventions*
Boston Scientific	Research/Research Grants	Modest (< $5,000)	*General Cardiology*
CathWorks	Consultant Fees/Honoraria	Modest (< $5,000)	*Noninvasive Imaging*
Edwards	Consultant Fees/Honoraria	Modest (< $5,000)	*Invasive CV Angio and Interventions*
Elixir Medical	Consultant Fees/Honoraria	Significant (>= $5,000)	*Invasive CV Angio and Interventions*
Magenta Medical	Consultant Fees/Honoraria	Modest (< $5,000)	*Invasive CV Angio and Interventions*
Medtronic	Research/Research Grants ‡ *SAFE PAD*	Significant (>= $5,000)	*Vascular Medicine*
Medtronic	Consultant Fees/Honoraria	Significant (>= $5,000)	*Stable Ischemic Heart Disease*
Shockwave	Consultant Fees/Honoraria	Modest (< $5,000)	*Invasive CV Angio and Interventions*

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (1)

Non-Commercial Enity Name	Relationship Category	Compensation Level	*Topic Area(s)*
Self			
FDA	Salary	Modest (< $5,000)	*Other*

Clinical Trial Enroller (2)

Trial Name	Trial Sponsor	Trial Funding Source
AGENT STANCE	Boston Scientific	
ELEVATE III	Magenta	Magenta

Institutional Financial Decision-Making Role (2)

Funding Source	Institutional Compensation Level
Beth Israel Deaconess Medical Center	Significant (>= $5,000)
Richard and Susan Smith Center for Outcomes Research in Cardiology	Significant (>= $5,000)

Expert Witness Testimony (4)

Year	Case Title	Represented	Description	Compensation
Self				
2026	Interventiona Cardiology	Defendant		Significant (>= $5,000)
2024	Coronary intervention	Defendant		Significant (>= $5,000)
2016	Coronary intervention	Defendant		Significant (>= $5,000)
2015	Coronary artery disease	Defendant † *Merck*		Significant (>= $5,000)

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 5/31/2026
URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 5/31/2026
URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 5/31/2026
URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 5/31/2026

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.